Is Disruption Just A Young Pup’s Game?
Older Dogs Are Seeking New Tricks When It Comes To Next-Level Business Models
Executive Summary
Big pharma has faced many evolutions to the pharma playbook of old. New technologies such as wearables introduce behavioral change to patients, while e-commerce giants such as Amazon seek a piece of the Rx action. The health care industry has done a reasonable job of weathering the storm inflicted on its core business model over the years, but it has yet to be a true disruptor. As the world marches on is pharma’s choice to disrupt, or inevitably be disrupted for good?
You may also be interested in...
Not All AI Companies Are A Success: The Woes Of Sensyne
The business founded by Lord Drayson has struggled to achieve commercial success for its artificial intelligence products.
Funding The Future: Accelerating The Long Walk To Innovation
In Vivo spoke with two company creators working in the biotech industry about their strategies for seeking new science and their funding philosophy when building the biotechs of tomorrow.
Partnerships Picks For GeNeuro’s MS Antibody
The Geneva-based biotech has been developing its antibody temelimab for the last 16 years. Data from its Phase II studies show its need for a big pharma development partner.